U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Cervical Adenocarcinoma

MedGen UID:
1793239
•Concept ID:
C5556798
•
Neoplastic Process

Definition

Cervical adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Cervical Adenocarcinoma

Professional guidelines

PubMed

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J
Future Oncol 2022 Jul;18(23):2495-2503. Epub 2022 Jun 15 doi: 10.2217/fon-2021-1579. PMID: 35703115
Impact of Histopathological Risk Factors on the Treatment of Stage IB-IIB Uterine Cervical Cancer.
Shimada M, Tokunaga H, Kigawa J, Yaegashi N
Tohoku J Exp Med 2020 Dec;252(4):339-351. doi: 10.1620/tjem.252.339. PMID: 33311005

Recent clinical studies

Etiology

Differentiated thyroid carcinoma: what the nonspecialists needs to know.
Hoff AO, Chaves ALF, de Oliveira TB, Ramos HE, Penna GC, Dos Santos LV, Maia AL, Brito DO, Vizzotto FP
Arch Endocrinol Metab 2024 Feb 29;68:e230375. doi: 10.20945/2359-4292-2023-0375. PMID: 38427812Free PMC Article
Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions.
Nishio H, Matsuda R, Iwata T, Yamagami W
Jpn J Clin Oncol 2024 May 7;54(5):516-520. doi: 10.1093/jjco/hyae019. PMID: 38366663Free PMC Article
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, Liu B, Li Z, Ji Q, Tang L, Deng Z, Ding Y, Fu W, Xie X, Li L, He X, Lv Z, Ma Q, Shen Z, Guo Z, Chen Z, Cui Y, Tan J, Gao Z, Jing S, Lu K, Luo X, Zhang Y, Fang Y, Li Z, Cheng Y, Lei S, Luan S, Chen G, Wang G, Wu L, Liu L
Clin Cancer Res 2023 Aug 1;29(15):2791-2799. doi: 10.1158/1078-0432.CCR-22-3613. PMID: 37184934
Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.
Lee JS, Lee JS, Yun HJ, Kim SM, Chang H, Lee YS, Chang HS, Park CS
J Clin Endocrinol Metab 2023 May 17;108(6):1370-1375. doi: 10.1210/clinem/dgac739. PMID: 36546348Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201

Diagnosis

Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF(V600E)-associated thyroid carcinoma.
Zhang P, Guan L, Sun W, Zhang Y, Du Y, Yuan S, Cao X, Yu Z, Jia Q, Zheng X, Meng Z, Li X, Zhao L
Clin Transl Med 2024 May;14(5):e1694. doi: 10.1002/ctm2.1694. PMID: 38797942Free PMC Article
Differentiated thyroid carcinoma: what the nonspecialists needs to know.
Hoff AO, Chaves ALF, de Oliveira TB, Ramos HE, Penna GC, Dos Santos LV, Maia AL, Brito DO, Vizzotto FP
Arch Endocrinol Metab 2024 Feb 29;68:e230375. doi: 10.20945/2359-4292-2023-0375. PMID: 38427812Free PMC Article
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA
Cell Rep Med 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. PMID: 35492873Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L
Cells 2020 Apr 25;9(5) doi: 10.3390/cells9051073. PMID: 32344931Free PMC Article

Therapy

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M
Biochim Biophys Acta Rev Cancer 2023 Jul;1878(4):188928. Epub 2023 May 29 doi: 10.1016/j.bbcan.2023.188928. PMID: 37257629
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M
Ann Oncol 2022 May;33(5):522-533. Epub 2022 Feb 14 doi: 10.1016/j.annonc.2022.02.001. PMID: 35176457
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, Won JK, Jung KC, Kwon D, Chung EJ, Hah JH, Paeng JC, Kim JH, Choi J, Kim OH, Oh JM, Ahn BC, Wirth LJ, Shin CH, Kim JI, Park YJ
J Clin Invest 2021 Sep 15;131(18) doi: 10.1172/JCI144847. PMID: 34237031Free PMC Article

Prognosis

Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy.
Turner N, Hamidi S, Ouni R, Rico R, Henderson YC, Puche M, Alekseev S, Colunga-Minutti JG, Zafereo ME, Lai SY, Kim ST, Cabanillas ME, Nurieva R
Front Immunol 2024;15:1369780. Epub 2024 May 29 doi: 10.3389/fimmu.2024.1369780. PMID: 38868771Free PMC Article
Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF(V600E)-associated thyroid carcinoma.
Zhang P, Guan L, Sun W, Zhang Y, Du Y, Yuan S, Cao X, Yu Z, Jia Q, Zheng X, Meng Z, Li X, Zhao L
Clin Transl Med 2024 May;14(5):e1694. doi: 10.1002/ctm2.1694. PMID: 38797942Free PMC Article
Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Zhao S, Zhao Y, Zhao Y, Wang G
Front Endocrinol (Lausanne) 2023;14:1320044. Epub 2024 Jan 19 doi: 10.3389/fendo.2023.1320044. PMID: 38313845Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma.
Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, Han P, Wang Y, Ji D, Gan H, Wei W, Lu Z, Qu N, Hu J, Hu X, Luo Z, Li H, Ji Q, Wang J, Zhang X, Wang YL
Nat Commun 2021 Oct 18;12(1):6058. doi: 10.1038/s41467-021-26343-3. PMID: 34663816Free PMC Article

Clinical prediction guides

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, Liu B, Li Z, Ji Q, Tang L, Deng Z, Ding Y, Fu W, Xie X, Li L, He X, Lv Z, Ma Q, Shen Z, Guo Z, Chen Z, Cui Y, Tan J, Gao Z, Jing S, Lu K, Luo X, Zhang Y, Fang Y, Li Z, Cheng Y, Lei S, Luan S, Chen G, Wang G, Wu L, Liu L
Clin Cancer Res 2023 Aug 1;29(15):2791-2799. doi: 10.1158/1078-0432.CCR-22-3613. PMID: 37184934
Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.
Lee JS, Lee JS, Yun HJ, Kim SM, Chang H, Lee YS, Chang HS, Park CS
J Clin Endocrinol Metab 2023 May 17;108(6):1370-1375. doi: 10.1210/clinem/dgac739. PMID: 36546348Free PMC Article
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA
Cell Rep Med 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. PMID: 35492873Free PMC Article
Laparoscopic total esophagectomy.
Swanstrom LL, Hansen P
Arch Surg 1997 Sep;132(9):943-7; discussion 947-9. doi: 10.1001/archsurg.1997.01430330009001. PMID: 9301605

Recent systematic reviews

Will targeted therapy hold its promise? An evidence-based review.
Murdoch D, Sager J
Curr Opin Oncol 2008 Jan;20(1):104-11. doi: 10.1097/CCO.0b013e3282f44b12. PMID: 18043264

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...